In CKD, once-daily empagliflozin reduced progression of kidney disease or CV death at 2 y

Y Diana Kwong; Chi-Yuan Hsu

doi:10.7326/J23-0009

In CKD, once-daily empagliflozin reduced progression of kidney disease or CV death at 2 y

Ann Intern Med. 2023 Mar;176(3):JC26. doi: 10.7326/J23-0009. Epub 2023 Mar 7.

Authors

Y Diana Kwong¹, Chi-Yuan Hsu¹

Affiliation

¹ University of California, San Francisco, San Francisco, California, USA (Y.D.K., C.H.).

PMID: 36877974
DOI: 10.7326/J23-0009

Abstract

EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117-27. 36331190.

Publication types

Comment

MeSH terms

Cardiovascular Diseases*
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Humans
Renal Insufficiency, Chronic* / complications
Renal Insufficiency, Chronic* / drug therapy
Risk Factors

Substances

empagliflozin